Target Identification/ Validation News for December 2009

AstraZeneca and the University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease

AstraZeneca and the University of Virginia in Charlottesville recently announced that they have entered into a strategic research collaboration to enhance the development of new treatments primarily for coronary artery disease with a secondary focus on peripheral vascular disease.
24 December, 2009

Thermo Fisher Scientific’s mass spectrometry technology helps Children’s Hospital Boston isolate biomarker for acute pediatric appendicitis

The Children’s Hospital research team believes the discovery will lead to more accurate and efficient diagnosis.
17 December, 2009

Mayo Clinic and the National Cancer Institute collaborate to develop and study cancer models of key tumourigenesis pathway involved in drug resistance

The National Cancer Institute has entered into a research and development collaboration with Mayo Clinic to expand on recent research discoveries at Mayo, where researchers have demonstrated the importance of a key protein involved in pancreatic and lung cancer.
09 December, 2009

Two heads are better than one in a new mode of antibiotic action.

An antibiotic that binds to a well-established target in a novel and unexpected way could be the inspiration for designing new, more potent antibiotic drugs.
04 December, 2009

First ever blueprint of a minimal cell is more complex than expected

EMBL and CRG scientists reveal what a self-sufficient cell can’t do without.
03 December, 2009

Target Identification/ Validation News for December 2009

Target Identification/ Validation News Archive

AstraZeneca and the University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease AstraZeneca and the University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease

Thermo Fisher Scientific’s mass spectrometry technology helps Children’s Hospital Boston isolate biomarker for acute pediatric appendicitis Thermo Fisher Scientific’s mass spectrometry technology helps Children’s Hospital Boston isolate biomarker for acute pediatric appendicitis

Two heads are better than one in a new mode of antibiotic action. Two heads are better than one in a new mode of antibiotic action.

First ever blueprint of a minimal cell is more complex than expected First ever blueprint of a minimal cell is more complex than expected

AstraZeneca and the University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease

Thermo Fisher Scientific’s mass spectrometry technology helps Children’s Hospital Boston isolate biomarker for acute pediatric appendicitis

Two heads are better than one in a new mode of antibiotic action.

First ever blueprint of a minimal cell is more complex than expected